BLOOMFIELD, Conn., Oct. 12, 2023 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its third quarter 2023 financial results on Thursday, November 2, 2023, and will host a conference call the same day.
Third quarter 2023 financial results will be released no later than 6:30 a.m. Eastern Time (ET). Management will review these results on a conference call beginning at 8:30 a.m. ET. The call-in numbers are as follows:
Live Call
(888) 566-1889 (Domestic)
(773) 799-3989 (International)
Passcode: 11022023
Replay
(800) 839-1171 (Domestic)
(203) 369-3030 (International)
It is strongly suggested that participants dial in to the conference call by 8:15 a.m. ET on November 2. A replay of the call will be available from 12:30 p.m. ET on November 2 until 11:59 p.m. ET on November 16, 2023. Additionally, the conference call will be available on a live internet webcast at this link. in the Investor Relations section of The Cigna Group's website. Please note that this feature will be in listen-only mode.
A copy of the company's news release and financial supplement will be available on The Cigna Group's website in the Investor Relations section at this link, no later than 6:30 a.m. ET on November 2.
About The Cigna Group
The Cigna Group (NYSE:CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Cigna Healthcare, Evernorth Health Services or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 countries and jurisdictions, and has more than 165 million customer relationships around the world. Learn more at thecignagroup.com.
Investor Relations Contact
Ralph Giacobbe
1 (860) 787-7968
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Justine Sessions
1 (860) 810-6523
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$333.01 |
| Daily Change: | 4.56 1.39 |
| Daily Volume: | 2,297,590 |
| Market Cap: | US$92.630B |
October 31, 2024 September 12, 2024 September 12, 2024 August 01, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
